Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Adult aHUS Patients Naive to Complement Inhibitor Therapy
NCT04889430Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Started Jan 2022; status: completed.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT04889430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889430.